The Serum Institute of India (SII), located in Pune, has introduced Cervavac, the country’s first quadrivalent Human Papillomavirus (qHPV) vaccine, designed for the prevention of cervical cancer. Developed and manufactured by SII, the vaccine has now been made available in the private market. Cervical cancer is a major concern in India, with the country accounting for 27% of global cases. The new vaccine, which targets four strains of HPV, is expected to significantly reduce the incidence of cervical cancer and related fatalities in India. Alongside private distribution, the Indian government is also planning to facilitate the widespread dissemination of the vaccine. The move aims to address the disparities in access to healthcare and ensure that the vaccine reaches a larger population, particularly in rural areas. With this development, India is taking a significant step forward in the fight against cervical cancer and prioritizing women’s health.
Indian-made Cervical Cancer Vaccine Now Available in Private Market
Pune-based Serum Institute of India has released Cervavac, the country's first quadrivalent Human Papillomavirus (qHPV) vaccine to combat cervical cancer, in the private market. The vaccine, which targets four strains of the virus, is said to be highly effective. Plans for government distribution are also in progress, aiming to make the vaccine more widely accessible and reduce the burden of cervical cancer in India.
Latest from Blog
Manu Chopra, CEO of Karya Inc., emphasized the importance of utilizing artificial intelligence (AI) to reduce
Italy has decided to withdraw from China's Belt and Road Initiative, becoming the only G7 nation
Zerodha's top executives collectively received a remuneration of about ₹200 crore in the financial year 2022-23,
New research suggests that radiotherapy may not be necessary for many patients with ductal carcinoma in
The US Space Force's X-37B space plane is gearing up for its seventh mission, after landing
